201 related articles for article (PubMed ID: 22689292)
1. Health economic assessment of ferric carboxymaltose in patients with iron deficiency and chronic heart failure based on the FAIR-HF trial: an analysis for the UK.
Gutzwiller FS; Schwenkglenks M; Blank PR; Braunhofer PG; Mori C; Szucs TD; Ponikowski P; Anker SD
Eur J Heart Fail; 2012 Jul; 14(7):782-90. PubMed ID: 22689292
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of ferric carboxymaltose in iron-deficient patients with chronic heart failure in Sweden.
Hofmarcher T; Borg S
J Med Econ; 2015; 18(7):492-501. PubMed ID: 25766863
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of implementing ESC guidelines for treatment of iron deficiency in heart failure in the Nordic countries.
Hofmarcher T; Cabrales Alin D; Linde C
Scand Cardiovasc J; 2018 Dec; 52(6):348-355. PubMed ID: 30457358
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and cost effectiveness of intravenous ferric carboxymaltose versus iron sucrose in adult patients with iron deficiency anaemia.
Basha A; Ibrahim MIM; Hamad A; Chandra P; Omar NE; Abdullah MAJ; Aldapt MB; Hussein RM; Mahfouz A; Adel AA; Shwaylia HM; Ekeibed Y; AbuMousa R; Yassin MA
PLoS One; 2021; 16(8):e0255104. PubMed ID: 34375369
[TBL] [Abstract][Full Text] [Related]
5. Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost-effectiveness analysis utilising AFFIRM-AHF.
McEwan P; Ponikowski P; Davis JA; Rosano G; Coats AJS; Dorigotti F; O'Sullivan D; Ramirez de Arellano A; Jankowska EA
Eur J Heart Fail; 2021 Oct; 23(10):1687-1697. PubMed ID: 34191394
[TBL] [Abstract][Full Text] [Related]
6. Cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anemia in England.
Iqbal TH; Kennedy N; Dhar A; Ahmed W; Pollock RF
J Med Econ; 2024; 27(1):392-403. PubMed ID: 38391240
[TBL] [Abstract][Full Text] [Related]
7. A Cost-effectiveness Analysis of Ferric Carboxymaltose in Patients With Iron Deficiency and Chronic Heart Failure in Spain.
Comín-Colet J; Rubio-Rodríguez D; Rubio-Terrés C; Enjuanes-Grau C; Gutzwiller FS; Anker SD; Ponikowski P
Rev Esp Cardiol (Engl Ed); 2015 Oct; 68(10):846-51. PubMed ID: 25649970
[TBL] [Abstract][Full Text] [Related]
8. Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France.
Bourguignon S; Faller M; Champs FO; Moutier H; Levesque K; Caranhac G; Cohen-Solal A
ESC Heart Fail; 2019 Jun; 6(3):559-569. PubMed ID: 31021531
[TBL] [Abstract][Full Text] [Related]
9. A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United Kingdom.
Pollock RF; Muduma G
J Med Econ; 2020 Jul; 23(7):751-759. PubMed ID: 32208038
[No Abstract] [Full Text] [Related]
10. Cost-utility of ferric carboxymaltose (Ferinject®) for iron-deficiency anemia patients with chronic heart failure in South Korea.
Lim EA; Sohn HS; Lee H; Choi SE
Cost Eff Resour Alloc; 2014; 12():19. PubMed ID: 25278814
[TBL] [Abstract][Full Text] [Related]
11. An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.
Pollock RF; Muduma G
Adv Ther; 2018 Dec; 35(12):2128-2137. PubMed ID: 30456520
[TBL] [Abstract][Full Text] [Related]
12. The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study.
Ponikowski P; Filippatos G; Colet JC; Willenheimer R; Dickstein K; Lüscher T; Gaudesius G; von Eisenhart Rothe B; Mori C; Greenlaw N; Ford I; Macdougall I; Anker SD;
Eur J Heart Fail; 2015 Mar; 17(3):329-39. PubMed ID: 25683972
[TBL] [Abstract][Full Text] [Related]
13. Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial.
Filippatos G; Farmakis D; Colet JC; Dickstein K; Lüscher TF; Willenheimer R; Parissis J; Gaudesius G; Mori C; von Eisenhart Rothe B; Greenlaw N; Ford I; Ponikowski P; Anker SD
Eur J Heart Fail; 2013 Nov; 15(11):1267-76. PubMed ID: 23787722
[TBL] [Abstract][Full Text] [Related]
14. The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study.
Comin-Colet J; Lainscak M; Dickstein K; Filippatos GS; Johnson P; Lüscher TF; Mori C; Willenheimer R; Ponikowski P; Anker SD
Eur Heart J; 2013 Jan; 34(1):30-8. PubMed ID: 22297124
[TBL] [Abstract][Full Text] [Related]
15. The effect of intravenous ferric carboxymaltose on red cell distribution width: a subanalysis of the FAIR-HF study.
Van Craenenbroeck EM; Conraads VM; Greenlaw N; Gaudesius G; Mori C; Ponikowski P; Anker SD
Eur J Heart Fail; 2013 Jul; 15(7):756-62. PubMed ID: 23639779
[TBL] [Abstract][Full Text] [Related]
16. Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carboxymaltose: FAIR-HF sub-analysis.
Gutzwiller FS; Pfeil AM; Comin-Colet J; Ponikowski P; Filippatos G; Mori C; Braunhofer PG; Szucs TD; Schwenkglenks M; Anker SD
Int J Cardiol; 2013 Oct; 168(4):3878-83. PubMed ID: 23870642
[TBL] [Abstract][Full Text] [Related]
17. Financial impact of intravenous iron treatments on the management of anaemia inpatients: a 1 year observational study.
Delpeuch A; Ruivard M; Abergel A; Aumaitre O; Boisgard S; Bagel S; Sautou V
Int J Clin Pharm; 2018 Jun; 40(3):686-692. PubMed ID: 29520555
[TBL] [Abstract][Full Text] [Related]
18. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†.
Ponikowski P; van Veldhuisen DJ; Comin-Colet J; Ertl G; Komajda M; Mareev V; McDonagh T; Parkhomenko A; Tavazzi L; Levesque V; Mori C; Roubert B; Filippatos G; Ruschitzka F; Anker SD;
Eur Heart J; 2015 Mar; 36(11):657-68. PubMed ID: 25176939
[TBL] [Abstract][Full Text] [Related]
19. Ferric carboxymaltose for patients with heart failure and iron deficiency in Italy: cost-effectiveness and budget impact.
Rognoni C; Gerzeli S
J Comp Eff Res; 2019 Oct; 8(13):1099-1110. PubMed ID: 31580153
[No Abstract] [Full Text] [Related]
20. Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose for the ambulatory treatment of severe iron deficiency.
Calvet X; Ruíz MÀ; Dosal A; Moreno L; López M; Figuerola A; Suarez D; Miquel M; Villoria A; Gené E
PLoS One; 2012; 7(9):e45604. PubMed ID: 23029129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]